eFFECTOR Therapeutics (EFTRW) Short Interest Ratio & Short Volume → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free EFTRW Stock Alerts $0.03 -0.01 (-25.64%) (As of 05/3/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media eFFECTOR Therapeutics Short Interest DataCurrent Short Volume10,700 sharesPrevious Short Volume4,300 sharesChange Vs. Previous Month+148.84%Dollar Volume Sold Short$373.43Short Interest Ratio / Days to Cover0.3Last Record DateApril 15, 2024Today's Trading Volume42,856 sharesAverage Trading Volume30,081 sharesToday's Volume Vs. Average142% Short Selling eFFECTOR Therapeutics ? Sign up to receive the latest short interest report for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatEFTRW Short Interest Over TimeEFTRW Days to Cover Over TimeEFTRW Percentage of Float Shorted Over Time Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… eFFECTOR Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202410,700 shares $373.43 +148.8%N/A0.3 $0.03 3/31/20244,300 shares $580.93 +53.6%N/A0.1 $0.14 3/15/20242,800 shares $365.60 -3.5%N/A0.1 $0.13 2/29/20242,900 shares $433.55 -31.0%N/A0.2 $0.15 2/15/20244,200 shares $449.40 +121.1%N/A0.4 $0.11 1/31/20241,900 shares $143.83 -9.5%N/A0.3 $0.08 Get the Latest News and Ratings for EFTRW and Related StocksEnter your email address below to receive the latest news and analysts' ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20242,100 shares $228.90 -34.4%N/A0.5 $0.11 12/31/20233,200 shares $472.00 +220.0%N/A2.2 $0.15 12/15/20231,000 shares $123.10 -75.0%N/A0.9 $0.12 11/30/20234,000 shares $587.60 -11.1%N/A1.4 $0.15 11/15/20234,500 shares $619.65 -10.0%N/A1.6 $0.14 10/31/20235,000 shares $700.00 +51.5%N/A1.4 $0.14 10/15/20233,300 shares $462.00 -17.5%N/A0.8 $0.14 9/30/20234,000 shares $304.00 -9.1%N/A0.8 $0.08 9/15/20234,400 shares $426.80 -62.1%N/A0.9 $0.10 8/31/202311,600 shares $2,088.00 -0.9%N/A2.6 $0.18 8/15/202311,700 shares $1,755.00 -16.4%N/A1.9 $0.15 7/31/202314,000 shares $2,100.00 -14.1%N/A2.4 $0.15 7/15/202316,300 shares $2,502.05 -15.5%N/A3.1 $0.15 6/30/202319,300 shares $3,348.55 -15.0%N/A4.2 $0.17 6/15/202322,700 shares $4,540.00 -47.2%N/A4.9 $0.20 5/31/202343,000 shares $7,310.00 +13.5%N/A9.8 $0.17 5/15/202337,900 shares $6,443.00 -0.3%N/A4.9 $0.17 4/30/202338,000 shares $5,320.00 -0.3%N/A4.2 $0.14 4/15/202338,100 shares $5,600.66 -0.3%N/A4.2 $0.15 3/31/202338,200 shares $4,935.44 -3.8%N/A4 $0.13 3/15/202339,700 shares $6,153.50 +415.6%N/A4.1 $0.16 2/28/20237,700 shares $843.15 -16.3%N/A0.8 $0.11 2/15/20239,200 shares $1,334.00 -51.6%N/A1.3 $0.15 1/31/202319,000 shares $2,654.30 -11.6%N/A3.1 $0.14 1/15/202321,500 shares $3,418.50 +6.4%N/A1.5 $0.16 12/30/202220,200 shares $3,306.74 -24.6%N/A1.4 $0.16 12/15/202226,800 shares $2,948.00 -23.9%N/A1.7 $0.11 11/30/202235,200 shares $4,118.40 -6.4%N/A2.1 $0.12 11/15/202237,600 shares $5,264.00 -20.3%N/A1.6 $0.14 10/31/202247,200 shares $4,720.00 -12.6%N/A1.3 $0.10 10/15/202254,000 shares $7,959.60 -3.1%N/A2 $0.15 9/30/202255,700 shares $11,329.38 -19.6%N/A2.1 $0.20 9/15/202269,300 shares $13,860.00 +919.1%N/A2.8 $0.20 8/31/20226,800 shares $884.00 -39.3%N/A0.3 $0.13Gold Mania (Ad)Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. EFTRW Short Interest - Frequently Asked Questions What is eFFECTOR Therapeutics' current short interest? Short interest is the volume of eFFECTOR Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 10,700 shares of EFTRW short. Learn More on eFFECTOR Therapeutics' current short interest. Is eFFECTOR Therapeutics' short interest increasing or decreasing? eFFECTOR Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 10,700 shares, an increase of 148.8% from the previous total of 4,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short eFFECTOR Therapeutics stock? Short selling EFTRW is an investing strategy that aims to generate trading profit from eFFECTOR Therapeutics as its price is falling. EFTRW shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against eFFECTOR Therapeutics? A short squeeze for eFFECTOR Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EFTRW, which in turn drives the price of the stock up even further. How often is eFFECTOR Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EFTRW, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: ATNFW Short Interest Data DRTSW Short Interest Data APLMW Short Interest Data ARTLW Short Interest Data BCTXW Short Interest Data CDIOW Short Interest Data CTCXW Short Interest Data SAVAW Short Interest Data CELUW Short Interest Data CLNNW Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EFTRW) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmith